The American Board of Psychiatry and Neurology has reviewed the 2017 Psychopharmacology Update and has approved this program as part of a comprehensive CME program, which is mandated by the ABMS as a necessary component of maintenance of certification (MOC). The activity awards 7 AMA PRA Category 1 CreditsTM and 7 Self-Assessment Category 1 CME credits.
Overview of the 16th Annual Psychopharmacology Update
This well-established one-day CME symposium offers an outstanding opportunity for education and networking with minimal disruption to your busy schedule. At this full-day course, nationally renowned faculty will cover Revolutionary Psychopharmacology: Innovative Therapies for Unment Psychiatric Needs. You will get in-depth analysis from our expert faculty and ample time to query them on topics that will help keep your practice ahead of the curve.
Who Should Attend
The 2017 Psychopharmacology Update is a CME conference designed for child and adolescent psychiatrists, general psychiatrists, geriatric psychiatrists, nurse practitioners, physician assistants, nurses, psychologists, social workers, and other mental health professionals interested in treating patients with psychiatric disorders to remission with measurement based care
Continuing Medical Education
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and Global Academy for Medical Education. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
The University of Cincinnati designates this Live Activity for a maximum of 7 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants Credit Designation
The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 CreditsTM from organizations accredited by the ACCME.
This activity is endorsed by Current Psychiatry.
At the conclusion of this activity, participants should be able to:
- Explain the options for managing the positive, negative, and cognitive symptoms of schizophrenia
- Explain how hyperthermia therapy may relieve depression previously resistant to pharmacotherapy
- Identify the differences among the antipsychotic medications in their neuroprotective properties as well as safety profiles
- Discuss the emerging science of neuroplasticity and treatments on the horizon that may preserve or reverse brain function
- Review the data on the efficacy and safety of long-acting injectable medication for the treatment of alcohol and opiate addiction
- Describe how hallucinogens can be used as treatments
- Implement evidence based treatments for TD, including innovative treatment